Crossmark

PM20D1 is a quantitative trait locus associated with Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1038/s41591-018-0013-y

Published Online: 2018-05-07

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sanchez-Mut, Jose V. https://orcid.org/0000-0002-9292-8521
Heyn, Holger https://orcid.org/0000-0002-3276-1889
Silva, Bianca A.

Dixsaut, Lucie

Garcia-Esparcia, Paula

Vidal, Enrique https://orcid.org/0000-0002-4217-1807
Sayols, Sergi https://orcid.org/0000-0002-3877-4170
Glauser, Liliane

Monteagudo-Sánchez, Ana https://orcid.org/0000-0002-1432-1185
Perez-Tur, Jordi https://orcid.org/0000-0002-9111-1712
Ferrer, Isidre

Monk, David

Schneider, Bernard https://orcid.org/0000-0001-5485-8748
Esteller, Manel

Gräff, Johannes
License Information

Text and Data Mining valid from 2018-05-01
More Information

Article History

Received: 22 July 2016

Accepted: 12 February 2018

First Online: 7 May 2018

Competing interests

: A provisional patent application has been filed on the use of PM20D1 methylation and haplotype as biomarkers for Alzheimer’s disease (International Application Number PCT/EP2017/067848), with J.V.S.-M., H.H., M.E. and J.G. listed as inventors.